Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(12), P. 797 - 809

Published: Aug. 3, 2023

Language: Английский

---

National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature

Hepatology, Journal Year: 2023, Volume and Issue: 79(3), P. 666 - 673

Published: Sept. 20, 2023

Background and Aims: The multisociety consensus nomenclature has renamed NAFLD to steatotic liver disease (SLD) with various subclassifications. There is a paucity of data regarding how the new modifies our understanding prevalence patient phenotypes. Approach Results: Using National Health Nutrition Examination Survey from January 2017 March 2020, we included all participants aged 18 years or above complete vibration-controlled transient elastography measures. SLD its subclassifications [metabolic dysfunction-associated (MASLD), MASLD + increased alcohol intake (MetALD), alcohol-associated (ALD), etiology-specific/cryptogenic] were defined according nomenclature. estimated, among key subgroups [age, sex, race/ethnicity, advanced fibrosis (liver stiffness measurement [LSM] ≥11.7 kPa)]. Among 7367 participants, 2549 had (mean age 51 y, 57.7% male, 63.2% non-Hispanic White). estimated was 34.2% (95% CI 31.9%–36.5%): 31.3% (29.2%–33.4%), MetALD 2% (1.6%–2.9%), ALD 0.7% (0.5–0.9%), etiology-specific/cryptogenic 0.03% (0.01%–0.08%). In exploratory analyses, classified as non-SLD (vs. without) higher mean number metabolic risk factors [2.7 (2.3–3.1) vs. 2.0 (1.9–2.0)] proportion average use ≥20 g/d (women)/≥30 (men) [20.9% (6.2%–51.3%) 7.2% (6.1%–8.4%)]. another analysis, increasing quantities remaining below threshold for associated in men, but not women. 99% overlap cases MASLD. Conclusions: Our findings highlight utility address deficiencies present old nomenclature, identify areas that require research further refine classifications SLD.

Language: Английский

---

Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population

Diabetes Research and Clinical Practice, Journal Year: 2024, Volume and Issue: 211, P. 111652 - 111652

Published: April 2, 2024

Language: Английский

---

Psychosocial risks in Metabolic dysfunction-associated steatotic liver disease

Expert Review of Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 15, 2025

Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly becoming more prevalent in the general population. MASLD common persons with low socioeconomic status (SES), yet little known about psychosocial challenges associated this disease, and clinical recommendations on how to approach are lacking.

Language: Английский

---

Patterns of dietary supplement use among United States patients with steatotic liver disease: Vitamins, minerals and botanicals

World Journal of Hepatology, Journal Year: 2025, Volume and Issue: 17(3)

Published: March 25, 2025

Dietary supplement (DS) usage among United States adults has significantly increased. Patients with steatotic liver disease (SLD) may have unique motivations to take DS in light of their condition and co-morbidities. To characterize use SLD patients explore for use. Adults ≥ 18 years old complete transient elastography dietary data from the National Health Nutrition Examination Survey between January 2017 March 2020 were studied. was defined using consensus criteria, combining clinical indicators thresholds. The Questionnaire (DSQ) used record participants' DSQ. Sample weights applied estimate national prevalence. Of 2413 participants SLD, 1058 reported DS, an estimated prevalence 44.8% [standard error (SE) 2.4] average 2.6 (SE 0.2) per person. Among taking DSQ, 53.2% 3.3) non-vitamin/non-mineral ones, 1.8 0.1) such supplements users more likely be female, higher levels education, greater food security (P < 0.02 all). most common follow doctor's advice (36.7%, SE 1.8), improve overall health (22.1%, 2.0), maintain (19.2%, 1.9). Nearly half individuals report DS. This study underscores pressing need deepen our understanding use/motivations develop tailored patient counseling strategies.

Language: Английский

---

Editorial: The heart of NAFLD

Frontiers in Medicine, Journal Year: 2023, Volume and Issue: 10

Published: May 22, 2023

EDITORIAL article Front. Med., 22 May 2023Sec. Gastroenterology Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1209625

Language: Английский

---

Quantitative ultrasound analysis for non-invasive assessment of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease

Clinical Hemorheology and Microcirculation, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Objective To evaluate the diagnostic performance of novel tissue attenuation imaging (TAI) and scatter distribution (TSI) tools in detecting grading hepatic steatosis using controlled parameter (CAP) as reference standard. Methods A total 185 participants with suspected metabolic dysfunction-associated steatotic liver disease (MASLD) were prospectively enrolled, all underwent CAP quantitative ultrasound (QUS) testing. Correlations between CAP, biological data, TAI TSI assessed. The influence factors well evaluated. Results QUS parameters (TAI TSI) showed good intra-observer reliability ICC 0.972 0.777, respectively. correlation was higher than that (0.724 vs 0.360, P < 0.05). Multivariate Regression analysis an important factor ( 0.001). area under ROC curve (CAP > 250 dB/m) for 0.876 (95% CI: 0.813–0.923; 0.0001) 0.797(95% 0.724–0.857; 0.001), respectively; sensitivity 67.18% 83.21%, specificity 95.65% 69.57%, cut-off values 0.93 dB/cm/MHz 91.28, When combined, 0.881, a 80.92% 82.61%. Delong test combined diagnosis equivalent to use alone Conclusion provided reliability, correlated helped detect stage steatosis.

Language: Английский

---

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology

Clinical and Molecular Hepatology, Journal Year: 2023, Volume and Issue: 29(2), P. 371 - 373

Published: March 14, 2023

Language: Английский

---

Cross‐sectional study on stigma and motivation to adhere to lifestyle modification among vulnerable populations with fatty liver disease

Obesity Science & Practice, Journal Year: 2023, Volume and Issue: 9(6), P. 581 - 589

Published: May 24, 2023

Adherence to lifestyle modification (diet, exercise, and alcohol cessation) for fatty liver disease (FLD) management remains challenging. The study examined stigma, barriers, factors associated with motivation adhere in a diverse vulnerable population FLD.From 2/19/2020 2/28/2022, 249 FLD patients within San Francisco safety-net hepatology clinics were surveyed along clinical data taken from medical records. Multivariable modeling assessed cross-sectional study.Median age was 53 years, 59% female, Hispanic, 25% Asian/Pacific Islander, 9% White, 2% Black, 79% non-English speakers, 64% had ≤ high school education, 82% reported <$30,000 annual income. Common comorbidities included hyperlipidemia (47%), hypertension (42%), diabetes (39%), heavy use (22%). Majority (78%) experiencing 41% extreme motivation, 58% ≥ two barriers. When controlling age, sex, Hispanic ethnicity, consumption, BMI, >high (coef 1.41, 95% CI 0.34-2.48), stigma 0.34, 0.07-0.62), depression -1.52, -2.79 -0.26) motivation.Stigma is commonly among patients. Interventions enhance patient education mental health support are critical management, especially populations.

Language: Английский

---

Long‐term all‐cause mortality of metabolic‐dysfunction associated steatotic liver disease based on body weight phenotypes following acute myocardial infarction: A retrospective cohort study

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 27(2), P. 683 - 696

Published: Nov. 11, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity increases risk of cardiovascular disease. This cohort study examines the prognostic value MASLD, across body weight categories, in a secondary preventative acute myocardial infarction (AMI) cohort.

Language: Английский

---